Stemline Therapeutics Inc (STML) Expected to Announce Earnings of -$0.71 Per Share

Share on StockTwits

Wall Street analysts predict that Stemline Therapeutics Inc (NASDAQ:STML) will post earnings of ($0.71) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.85) to ($0.67). Stemline Therapeutics posted earnings of ($0.93) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.7%. The business is scheduled to announce its next quarterly earnings results on Friday, March 15th.

According to Zacks, analysts expect that Stemline Therapeutics will report full year earnings of ($2.80) per share for the current fiscal year, with EPS estimates ranging from ($2.93) to ($2.74). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.31) per share, with EPS estimates ranging from ($2.62) to $1.52. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06).

STML has been the topic of several recent research reports. HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 10th. BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 16th. Finally, Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Stemline Therapeutics in a research report on Monday, November 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Stemline Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $26.32.

In other news, COO Kenneth Hoberman sold 26,296 shares of the company’s stock in a transaction that occurred on Monday, November 26th. The stock was sold at an average price of $11.85, for a total transaction of $311,607.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its stake in Stemline Therapeutics by 6.3% in the 3rd quarter. BlackRock Inc. now owns 1,969,492 shares of the biopharmaceutical company’s stock valued at $32,694,000 after purchasing an additional 116,672 shares during the last quarter. Vanguard Group Inc. raised its stake in Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after purchasing an additional 18,487 shares during the last quarter. Nexthera Capital LP increased its stake in shares of Stemline Therapeutics by 4.0% in the 3rd quarter. Nexthera Capital LP now owns 582,070 shares of the biopharmaceutical company’s stock worth $9,662,000 after acquiring an additional 22,553 shares during the last quarter. Northern Trust Corp increased its stake in shares of Stemline Therapeutics by 12.5% in the 2nd quarter. Northern Trust Corp now owns 380,378 shares of the biopharmaceutical company’s stock worth $6,106,000 after acquiring an additional 42,262 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in shares of Stemline Therapeutics by 20.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock worth $4,316,000 after acquiring an additional 45,000 shares during the last quarter. 64.20% of the stock is owned by institutional investors and hedge funds.

Stemline Therapeutics stock traded down $0.19 during mid-day trading on Monday, hitting $9.98. The company had a trading volume of 247,177 shares, compared to its average volume of 411,752. Stemline Therapeutics has a 12-month low of $9.65 and a 12-month high of $20.55.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Further Reading: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.